Dri Cotinine Eia Assay
510(k) K030649
Active
Valid until
No date given
FDA recalls
None found
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE 510(k) | NumberK030649 | Date22 May 2003 | StatusActive |
| European Union | CE/IVDD EUDAMED | Number— | Date— | StatusActive |
Official records
From the FDA record
- Received by the FDA
- 28 Feb 2003
- FDA decision
- 22 May 2003 (Substantially Equivalent)
- FDA review time
- 83 days from receipt to decision
- Public document
- 510(k) summary on file with the FDA
Across registries
- FDA 510(k) K030649 decided 22 May 2003 Active
- EUDAMED Active
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
- European Union
- United States
Specification
- 510(k) Number
- FDA product code
- MRS
- FDA applicant
- Microgenics Corp.
- Device class
- Class I
- Regulation
- 21 CFR Part 862.3220
- Advisory committee
- Clinical Toxicology
- FDA decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 25 Sep 2026
The Dri Cotinine Eia Assay is a liquid ready-to-use homogeneous enzyme immunoassay that uses specific antibodies to detect cotinine in urine. It is based on competition between a drug labeled with glucose-6-phosphate dehydrogenase enzyme and free drug from the urine sample for a fixed amount of specific antibody binding sites. The assay is intended for in vitro diagnostic use only.
The Dri Cotinine Eia Assay is intended for the qualitative and semi-quantitative determination of cotinine in human urine at a cutoff level of 500 ng/mL. It is supplied as a liquid, ready-to-use homogeneous enzyme immunoassay and is regulated under FDA 510(k) and IVDD authorizations.
Similar devices
Other devices filed under FDA product code MRS (Test System, Nicotine, Cotinine, Metabolites).